This Oral Solid Dosage Contract Manufacturing market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $39.39 billion in 2024 to $42.51 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to the growing global population, prevalence of chronic diseases, and rise in focus on research and development.
The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $56.89 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing outsourcing by pharmaceutical companies, advancements in drug delivery technology, and increasing drug development activities. Major trends in the forecast period include advancements in drug delivery technology, integration of 3D printing, and advancements in controlled-release technologies.
The surge in demand for generic drugs is anticipated to drive the growth of the oral solid dosage contract manufacturing market in the coming years. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The increasing demand for generic drugs is fueled by factors such as patent expirations, cost containment initiatives, regulatory incentives, and efforts to expand access to healthcare. Oral solid dosage contract manufacturing plays a pivotal role in facilitating the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance operational efficiency, reduce costs, ensure high-quality production, and expedite the introduction of products to the market. For example, in 2022, the Food and Drug Administration (FDA) estimated that 91% of all prescriptions in the USA were filled with generic drugs, with over 32,000 generic drugs approved by the FDA. Consequently, the demand for generic drugs propels the growth of the oral solid dosage contract manufacturing market.
Key players in the oral solid dosage contract manufacturing market are concentrating on developing innovative solutions, such as continuous manufacturing lines, to fortify their position in the market. A continuous manufacturing line refers to a production facility or system that employs continuous manufacturing processes to produce pharmaceuticals or other products. For instance, in January 2023, WuXi STA, a pharmaceutical company based in China, inaugurated its first continuous manufacturing line for oral solid pharmaceutical products. This state-of-the-art facility represents a significant advancement in pharmaceutical production, harnessing continuous manufacturing principles to enhance efficiency, quality, and flexibility in drug manufacturing processes. This enhanced agility streamlines production timelines and minimizes downtime, ultimately expediting the delivery of essential medications to patients.
In August 2022, Catalent Inc., a US-based pharmaceutical company, completed the acquisition of Metrics Contract Services for $475 million. Through this acquisition, Catalent seeks to broaden its capabilities in the development and manufacturing of oral solid dosage forms. Metrics Contract Services is a US-based full-service contract development and manufacturing organization (CDMO) specializing in oral dosage forms.
Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation.
Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2024. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Oral solid dosage contract manufacturing involves outsourcing the production of oral solid dosage forms of pharmaceuticals to third-party manufacturers. This strategy enables pharmaceutical companies to concentrate on their core activities, such as research, development, and marketing, while utilizing the expertise and capabilities of contract manufacturing organizations (CMOs) to efficiently produce high-quality oral solid dosage pharmaceuticals.
The main product types in oral solid dosage contract manufacturing include tablets, capsules, powders, granules, and other forms. Tablets are small, solid masses of medicine containing an active drug and excipients. The services offered encompass drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, and other applications. The therapeutic areas covered include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other therapeutic areas. The end users of these services are large companies, as well as medium and small companies.
The oral solid dosage contract manufacturing market research report is one of a series of new reports that provides oral solid dosage contract manufacturing market statistics, including oral solid dosage contract manufacturing industry global market size, regional shares, competitors with a oral solid dosage contract manufacturing market share, detailed oral solid dosage contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the oral solid dosage contract manufacturing industry. This oral solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oral solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as formulation development, analytical and stability testing, and quality assurance and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral solid dosage contract manufacturing market also consists of sales of orally disintegrating tablets (ODTS), lozenges, and chewing gums. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $39.39 billion in 2024 to $42.51 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to the growing global population, prevalence of chronic diseases, and rise in focus on research and development.
The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $56.89 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing outsourcing by pharmaceutical companies, advancements in drug delivery technology, and increasing drug development activities. Major trends in the forecast period include advancements in drug delivery technology, integration of 3D printing, and advancements in controlled-release technologies.
The surge in demand for generic drugs is anticipated to drive the growth of the oral solid dosage contract manufacturing market in the coming years. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The increasing demand for generic drugs is fueled by factors such as patent expirations, cost containment initiatives, regulatory incentives, and efforts to expand access to healthcare. Oral solid dosage contract manufacturing plays a pivotal role in facilitating the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance operational efficiency, reduce costs, ensure high-quality production, and expedite the introduction of products to the market. For example, in 2022, the Food and Drug Administration (FDA) estimated that 91% of all prescriptions in the USA were filled with generic drugs, with over 32,000 generic drugs approved by the FDA. Consequently, the demand for generic drugs propels the growth of the oral solid dosage contract manufacturing market.
Key players in the oral solid dosage contract manufacturing market are concentrating on developing innovative solutions, such as continuous manufacturing lines, to fortify their position in the market. A continuous manufacturing line refers to a production facility or system that employs continuous manufacturing processes to produce pharmaceuticals or other products. For instance, in January 2023, WuXi STA, a pharmaceutical company based in China, inaugurated its first continuous manufacturing line for oral solid pharmaceutical products. This state-of-the-art facility represents a significant advancement in pharmaceutical production, harnessing continuous manufacturing principles to enhance efficiency, quality, and flexibility in drug manufacturing processes. This enhanced agility streamlines production timelines and minimizes downtime, ultimately expediting the delivery of essential medications to patients.
In August 2022, Catalent Inc., a US-based pharmaceutical company, completed the acquisition of Metrics Contract Services for $475 million. Through this acquisition, Catalent seeks to broaden its capabilities in the development and manufacturing of oral solid dosage forms. Metrics Contract Services is a US-based full-service contract development and manufacturing organization (CDMO) specializing in oral dosage forms.
Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation.
Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2024. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Oral solid dosage contract manufacturing involves outsourcing the production of oral solid dosage forms of pharmaceuticals to third-party manufacturers. This strategy enables pharmaceutical companies to concentrate on their core activities, such as research, development, and marketing, while utilizing the expertise and capabilities of contract manufacturing organizations (CMOs) to efficiently produce high-quality oral solid dosage pharmaceuticals.
The main product types in oral solid dosage contract manufacturing include tablets, capsules, powders, granules, and other forms. Tablets are small, solid masses of medicine containing an active drug and excipients. The services offered encompass drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, and other applications. The therapeutic areas covered include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other therapeutic areas. The end users of these services are large companies, as well as medium and small companies.
The oral solid dosage contract manufacturing market research report is one of a series of new reports that provides oral solid dosage contract manufacturing market statistics, including oral solid dosage contract manufacturing industry global market size, regional shares, competitors with a oral solid dosage contract manufacturing market share, detailed oral solid dosage contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the oral solid dosage contract manufacturing industry. This oral solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oral solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as formulation development, analytical and stability testing, and quality assurance and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral solid dosage contract manufacturing market also consists of sales of orally disintegrating tablets (ODTS), lozenges, and chewing gums. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Oral Solid Dosage Contract Manufacturing Market Characteristics3. Oral Solid Dosage Contract Manufacturing Market Trends and Strategies4. Oral Solid Dosage Contract Manufacturing Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Oral Solid Dosage Contract Manufacturing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Oral Solid Dosage Contract Manufacturing Market34. Recent Developments in the Oral Solid Dosage Contract Manufacturing Market
5. Global Oral Solid Dosage Contract Manufacturing Growth Analysis and Strategic Analysis Framework
6. Oral Solid Dosage Contract Manufacturing Market Segmentation
7. Oral Solid Dosage Contract Manufacturing Market Regional and Country Analysis
8. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market
9. China Oral Solid Dosage Contract Manufacturing Market
10. India Oral Solid Dosage Contract Manufacturing Market
11. Japan Oral Solid Dosage Contract Manufacturing Market
12. Australia Oral Solid Dosage Contract Manufacturing Market
13. Indonesia Oral Solid Dosage Contract Manufacturing Market
14. South Korea Oral Solid Dosage Contract Manufacturing Market
15. Western Europe Oral Solid Dosage Contract Manufacturing Market
16. UK Oral Solid Dosage Contract Manufacturing Market
17. Germany Oral Solid Dosage Contract Manufacturing Market
18. France Oral Solid Dosage Contract Manufacturing Market
19. Italy Oral Solid Dosage Contract Manufacturing Market
20. Spain Oral Solid Dosage Contract Manufacturing Market
21. Eastern Europe Oral Solid Dosage Contract Manufacturing Market
22. Russia Oral Solid Dosage Contract Manufacturing Market
23. North America Oral Solid Dosage Contract Manufacturing Market
24. USA Oral Solid Dosage Contract Manufacturing Market
25. Canada Oral Solid Dosage Contract Manufacturing Market
26. South America Oral Solid Dosage Contract Manufacturing Market
27. Brazil Oral Solid Dosage Contract Manufacturing Market
28. Middle East Oral Solid Dosage Contract Manufacturing Market
29. Africa Oral Solid Dosage Contract Manufacturing Market
30. Oral Solid Dosage Contract Manufacturing Market Competitive Landscape and Company Profiles
31. Oral Solid Dosage Contract Manufacturing Market Other Major and Innovative Companies
35. Oral Solid Dosage Contract Manufacturing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Oral Solid Dosage Contract Manufacturing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on oral solid dosage contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oral solid dosage contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral solid dosage contract manufacturing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Tablets; Capsules; Powders; Granules; Other Product Types2) By Service: Drug Product Development; Fill Finish Product Manufacturing; API Manufacturing; Packaging and Labelling; Other Applications
3) By Therapeutic Area: Oncology; Cardiovascular Diseases; Metabolic Disorders; Neurological Disorders; infectious Diseases; Gastrointestinal Diseases; Other Therapeutic Areas
4) By End User: Large Size Companies; Medium and Small Size Companies
Subsegments:
1) By Tablets: Compressed Tablets; Effervescent Tablets; Chewable Tablets; Coated Tablets (Enteric, Film Coated); Sustained or Controlled Release Tablets2) By Capsules: Hard Gelatin Capsules; Soft Gel Capsules; Vegetarian Capsules; Liquid-Filled Capsules; Delayed Release Capsules
3) By Powders: Powders for Oral Suspension; Powders for Direct Compression; Powders for Mixing or Blending; Instant Dissolving Powders
4) By Granules: Granules for Direct Compression; Granules for Tabletting; Effervescent Granules; Delayed or Controlled Release Granules
5) By Other Product Types: Lozenges; Oral Strips; Oral Thin Films; Effervescent Tablets or Granules
Key Companies Mentioned: Pfizer Inc.; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Amgen Inc.; Merck KGaA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Oral Solid Dosage Contract Manufacturing market report include:- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Amgen Inc.
- Merck KGaA
- Siemens Healthineers AG
- Evonik Industries AG
- Teva Pharmaceutical Industries Ltd.
- Lonza Group AG
- Catalent Inc.
- Patheon Pharma Services
- Fareva Holding SA
- Piramal Enterprises Limited
- Hetero Drugs Limited
- Siegfried Holding AG
- Recipharm AB
- Almac Group Limited
- Aenova Holding GmbH
- Jubilant Pharmova Limited
- Cambrex Corporation
- International Chemical Investors Group (ICIG) operates under the CordenPharma brand
- Ajinomoto Co. Inc.
- Hovione Holding Ltd.
- Alcami Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 42.51 Billion |
Forecasted Market Value ( USD | $ 56.89 Billion |
Compound Annual Growth Rate | 7.6% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |